Radiologist review versus group peer review of claimed responses in a phase II study on high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the EORTC Soft Tissue and Bone Sarcoma Group

被引:3
作者
Gwyther, SJ
Nielsen, OS
Judson, IR
van Glabbeke, M
Verweij, J
机构
[1] E Surrey Hosp, Surrey & Sussex NHS Trust, Surrey RH1 5RH, England
[2] Aarhus Univ Hosp, DK-800 Aarhus C, Denmark
[3] Inst Canc Res, CRC, Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England
[4] EORTC Data Ctr, B-1200 Brussels, Belgium
[5] Rotterdam Canc Inst, Daniel den Hoed Klin, NL-3008 AE Rotterdam, Netherlands
[6] Univ Hosp, NL-3008 AE Rotterdam, Netherlands
关键词
claimed responses; independent radiological; review; peer review; response rate;
D O I
10.1097/00001813-200007000-00003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The Soft Tissue and Bone Sarcoma Group (STBSG) of the EORTC ran a phase II study to assess the therapeutic activity of high-dose ifosfamide in patients with advanced soft tissue sarcomas by means of response rate (RR). Investigators claiming a response submitted the relevant chest radiographs (CXR) or scans to two other members of the STBSG for peer review. The reviewers completed a questionnaire indicating overall response or reasons for rejecting the claimed responses. An independent radiologist also reviewed the cases and he was blinded to the results of the peer review until the study was concluded. Twenty-two patients were reviewed by the radiologist and peer review, and the completed questionnaires were retrospectively reviewed. Two differences were noted, one partial responder (PR) was regarded as stable disease by the radiologist and one PR by peer review was determined a complete response by the radiologist. The radiologist found subsequent evidence of progressive disease in three patients who initially showed a PR, whilst the review group noted only one. This study suggests peer review in this tumor type is a satisfactory method of achieving an accurate, objective RR. [(C) 2000 Lippincott Williams & Wilkins].
引用
收藏
页码:433 / 437
页数:5
相关论文
共 15 条
[1]   Phase II study of gemcitabine in patients with advanced pancreatic cancer [J].
Carmichael, J ;
Fink, U ;
Russell, RCG ;
Spittle, MF ;
Harris, AL ;
Spiessi, G ;
Blatter, J .
BRITISH JOURNAL OF CANCER, 1996, 73 (01) :101-105
[2]   ADVANCED BREAST-CANCER - A PHASE-II TRIAL WITH GEMCITABINE [J].
CARMICHAEL, J ;
POSSINGER, K ;
PHILLIP, P ;
BEYKIRCH, M ;
KERR, H ;
WALLING, J ;
HARRIS, AL .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (11) :2731-2736
[3]   EUROPEAN-CANADIAN RANDOMIZED TRIAL OF PACLITAXEL IN RELAPSED OVARIAN-CANCER - HIGH-DOSE VERSUS LOW-DOSE AND LONG VERSUS SHORT INFUSION [J].
EISENHAUER, EA ;
HUININK, WWT ;
SWENERTON, KD ;
GIANNI, L ;
MYLES, J ;
VANDERBURG, MEL ;
KERR, I ;
VERMORKEN, JB ;
BUSER, K ;
COLOMBO, N ;
BACON, M ;
SANTABARBARA, P ;
ONETTO, N ;
WINOGRAD, B ;
CANETTA, R .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (12) :2654-2666
[4]   Experience with independent radiological review during a topotecan trial in ovarian cancer [J].
Gwyther, S ;
Bolis, G ;
Gore, M ;
Huinink, WT ;
Verweij, J ;
Hudson, IR ;
Despax, R ;
JimenezLacave, A .
ANNALS OF ONCOLOGY, 1997, 8 (05) :463-468
[5]   Response assessment using radiological methods [J].
Gwyther, SJ .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 1999, 30 (01) :45-62
[6]   Results of an independent oncology review board of pivotal clinical trials of gemcitabine in non-small cell lung cancer [J].
Gwyther, SJ ;
Aapro, MS ;
Hatty, SR ;
Postmus, PE ;
Smith, IE .
ANTI-CANCER DRUGS, 1999, 10 (08) :693-698
[7]  
GWYTHER SJ, 1995, LUNG CANC THER, V10, P301
[8]   ORAL ETOPOSIDE IS ACTIVE AGAINST PLATINUM-RESISTANT EPITHELIAL OVARIAN-CANCER [J].
HOSKINS, PJ ;
SWENERTON, KD .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (01) :60-63
[9]   IFOSFAMIDE AND MESNA IN PREVIOUSLY TREATED ADVANCED EPITHELIAL OVARIAN-CANCER - ACTIVITY IN PLATINUM-RESISTANT DISEASE [J].
MARKMAN, M ;
HAKES, T ;
REICHMAN, B ;
LEWIS, JL ;
RUBIN, S ;
JONES, W ;
ALMADRONES, L ;
PIZZUTO, F ;
HOSKINS, W .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (02) :243-248
[10]  
NIELSEN OS, IN PRESS EUR J CANC